GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-02|

Eli Lilly Caps Insulin At $35 A Month, Widening Access For Americans

by Joy Lin
Share To

In a bid to make it easier for people with diabetes to access insulin, Eli Lilly has announced a series of price cuts of up to 70% to its insulin products. Furthermore, the company is expanding its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.  

Lilly Slashes Branded Insulin Prices by 70%

Lilly will cut the list price of its non-branded Insulin Lispro Injection 100 units/mL to $25 a vial. When the price change takes effect on May 1, 2023, it will be the lowest list-priced mealtime insulin available, costing less than a Humalog vial in 1999. 

The price of Humalog, Lilly’s branded insulin lispro injection and most commonly prescribed insulin, and Humulin (insulin human) injection will be slashed by 70%. The price change will take effect in the fourth quarter of 2023. 

Lilly is also launching Rezvoglar (insulin glargine-algr), an injectable biosimilar to Lantus (insulin glargine) injection. On top of being interchangeable with Lantus, Rezvoglar will cost $92 per five pack of KwikPens, a 78% discount to Lantus. The biosimilar product is expected to be available from April 1, 2023. 

According to the Centers for Disease Control and Prevention (CDC), around 37.3 million Americans —about 1 in 10 — have diabetes. 

“While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change,” said David A. Ricks, Lilly’s Chair and CEO. “The aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes.”

Related Article: Biden’s New Executive Order Directs HHS to Find Ways to Lower Drug Prices

Lilly Caps Out-Of-Pocket Costs of Insulin at $35

As the cuts will take time for the insurance and pharmacy system to implement, Lilly has moved to cap out-of-pocket costs at $35 at participating retail pharmacies for people with diabetes with commercial insurance using Lilly insulin. 

“We are driving for change in repricing older insulins, but we know that 7 out of 10 Americans don’t use Lilly insulin. We are calling on policymakers, employers and others to join us in making insulin more affordable,” continued Ricks. 

“For the past century, Lilly has focused on inventing new and improved insulins and other medicines that address the impact of diabetes and improve patient outcomes. Our work to discover new and better treatments is far from over. We won’t stop until all people with diabetes are in control of their disease and can get the insulin they need.”

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
Eli Lilly Steals the Spotlight at JPM 2025 with $2.5 Billion Power Move Acquisition
2025-01-16
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top